RE
Revelation Biosciences, Inc.
REVB · NASDAQ
$0.93 -4.90% (-$0.05)
1M -14.64%
Market Cap $3.71M
P/E Ratio -
Div. Yield -
ROE 100.20%
Bulios Fair Price
$0.72
22.6% downside
Current Price
$0.93
Undervalued Fair Value Overvalued
According to Bulios Fair Price, REVB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.37x
EV/FFO N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 103.44%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 100.20%
ROA 86.02%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 6.21x
Debt/Equity 0.07x
Net debt/EBITDA N/A
Stability
19 /100
Unstable EPS volatility 594.17%
Profitable years 0
Beta -0.17x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about REVB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
James Rolke
Employees
8
Headquarters
San Diego
Upcoming events
05 NOV
Earnings
Upcoming earnings report